X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Tiziana’s intranasal TZLS-401 (foralumab), is the only fully human anti-CD3 mAb that is being evaluated in patients with moderate Alzheimer’s disease.
Lead Product(s): Foralumab
Therapeutic Area: Neurology Product Name: TZLS-401
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2024
Details:
TZLS-401 (foralumab) is the only fully human anti-CD3 monoclonal antibody (mAb), it is under phase 2 clinical development for the treatment of non-active secondary progressive Multiple Sclerosis.
Lead Product(s): Foralumab
Therapeutic Area: Neurology Product Name: TZLS-401
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2024
Details:
TZLS-401 (foralumab) is the only fully human anti-CD3 monoclonal antibody (mAb), it is under phase 2 clinical development for the treatment of non-active secondary progressive Multiple Sclerosis.
Lead Product(s): Foralumab
Therapeutic Area: Neurology Product Name: TZLS-401
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2024
Details:
Tiziana’s intranasal TZLS-401 (foralumab), is the only fully human anti-CD3 mAb and has demonstrated a favorable safety profile and clinical response in patients with non-active secondary progressive multiple sclerosis.
Lead Product(s): Foralumab
Therapeutic Area: Neurology Product Name: TZLS-401
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2024
Details:
TZLS-401 (foralumab) is the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function. It is under phase 2 clinical development for the treatment of Multiple Sclerosis.
Lead Product(s): Foralumab
Therapeutic Area: Neurology Product Name: TZLS-401
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2024
Details:
Tiziana’s intranasal TZLS-401 (foralumab), is the only fully human anti-CD3 mAb and has demonstrated a favorable safety profile and clinical response in patients with non-active secondary progressive multiple sclerosis.
Lead Product(s): Foralumab
Therapeutic Area: Neurology Product Name: TZLS-401
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2024
Details:
TZLS-401 (foralumab) is the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function. It is under phase 2 clinical development for the treatment of Multiple Sclerosis.
Lead Product(s): Foralumab
Therapeutic Area: Neurology Product Name: TZLS-401
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
TZLS-401 (foralumab) is the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function. It is under phase 2 clinical development for the treatment of Multiple Sclerosis.
Lead Product(s): Foralumab
Therapeutic Area: Neurology Product Name: TZLS-401
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
TZLS-401 (foralumab) is a CD3 Inhibitor antibody drug administered through intranasal spray for the treatment non-active secondary-progressive multiple sclerosis.
Lead Product(s): Foralumab
Therapeutic Area: Neurology Product Name: TZLS-401
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Details:
Tiziana’s intranasal TZLS-401 (foralumab), is the only fully human anti-CD3 mAb and has demonstrated a favorable safety profile and clinical response in patients with Multiple Sclerosis.
Lead Product(s): Foralumab
Therapeutic Area: Neurology Product Name: TZLS-401
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
